Results 61 to 70 of about 46,962 (257)

Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji   +17 more
wiley   +1 more source

Dasatinib-Related Chylothorax

Turkish Journal of Hematology, 2015
Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax
Yen Min Huang, Cheng Hsu Wang, Jen Seng Huang, Kun Yun Yeh, Chien Hong Lai, Tsung Han Wu, Pei Hung Chang, Yueh Shih Chang, Yii Jenq Lan   +8 more
doaj   +1 more source

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors [PDF]

, 2014
Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR-ABL which activates a number of signal transduction pathways, including PI3K/AKT signaling and consequently inactivates FOXO transcription factors.
Bhatia, Birkenkamp, Breitling, Bruennert, Brunet, Burgering, Chomel, Chu, Copland, Corbin, Druker, Duy, Essafi, Fernandez de Mattos, Ghaffari, Goldman, Graham, Hamilton, Hurtz, Ito, Jorgensen, Kikuchi, Komatsu, Koschmieder, Mahon, Matsumoto, Miyamoto, Naka, Pellicano, Pellicano, Pellicano, Ross, Ross, Rowley, Sarbassov, Skorski, Tothova, Tothova, Trotman   +38 more
core   +2 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice. [PDF]

PLoS ONE, 2014
This study aimed to determine whether the multi-kinase inhibitor dasatinib would provide an effective therapy for myeloproliferative diseases (MPDs) involving c-Cbl mutations.
Johanna M Duyvestyn, Samuel J Taylor, Samantha A Dagger, Marlene Orandle, Herbert C Morse, Christine B F Thien, Wallace Y Langdon   +6 more
doaj   +1 more source

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. [PDF]

, 2012
BackgroundSrc inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.MethodsPatients had ECOG performance status 0-2 and normal organ function ...
Algazi, AP, Andrews, SC, Daud, AI, DeConti, RC, Hwang, J, McCalmont, T, Messina, JL, Munster, PN, Sondak, VK, Urbas, P, Weber, JS   +10 more
core  

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. [PDF]

, 2013
PurposeDasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose ...
Chen, Tai-Tsang, Hochhaus, Andreas, Kantarjian, Hagop M, Roy, Amit, Shah, Neil P, Wang, Xiaoning   +5 more
core   +2 more sources

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts

Molecular Cancer, 2010
Cancer associated fibroblasts (CAFs) play a critical role for growth, invasion, and metastasis of cancer. Therefore, targeting CAFs with small molecule inhibitors may be an attractive anti-tumor strategy. The current study aims to identify small molecule
van der Kuip Heiko, Friedel Godehard, Sonnenberg Maike, Mürdter Thomas E, Schmid Jens O, Haubeiss Silke, Aulitzky Walter E   +6 more
doaj   +1 more source

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. [PDF]

, 2015
In glioblastoma (GBM), the EGF receptor (EGFR) and Src family kinases (SFKs) contribute to an aggressive phenotype. EGFR may be targeted therapeutically; however, resistance to EGFR-targeting drugs such as Erlotinib and Gefitinib develops quickly.
Cavenee, WK, Furnari, FB, Gonias, SL, Hu, J, Muller, KA, VandenBerg, SR   +5 more
core